Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of Tilavonemab in PSP
NCT03391765Phase 2Terminated
- Sponsor
- AbbVie Inc.
- Start
- Jan 2018
- Primary completion
- Dec 2019
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of tilavonemab in progressive supranuclear palsy (PSP), sponsored by AbbVie Inc.. Started Jan 2018; status: terminated.
02
Drugs
tilavonemab
03
Conditions
progressive supranuclear palsy (PSP)
Beyond the preview
Go deeper on NCT03391765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03391765.